var tmpLoc = window.location.toString();
tmpLoc.search(/webs007/i) > 0?_server="http://webs007.ccit.bcm.tmc.edu/development/lipidsonline":_server="http://www.lipidsonline.org";
scriptpath=_server+"/_menu/";
_isHome==1?_menuTop=131:_menuTop=74;
_globalRawCSS = "rawcss=padding:1px 7px;";

_menuCloseDelay=150           // The time delay for menus to remain visible on mouse out
_menuOpenDelay=150             // The time delay before menus open on mouse over
horizontalMenuDelay = true
_followSpeed=5                // Follow scrolling speed
_followRate=40                // Follow scrolling Rate
_subOffsetTop=0               // Sub menu top offset
_subOffsetLeft=-4            // Sub menu left offset
_scrollAmount=3               // Only needed for Netscape 4.x
_scrollDelay=20               // Only needed for Netcsape 4.x
with(menuStyle=new mm_style()){
onbgcolor="#949187";      // the color of the menu items when they are rolled over
oncolor="#FFFFFF";        // the color of the menu text when they are rolled over
offbgcolor="#615F58";     // the color of the menu items not being rolled over
offcolor="#FFFFFF";       // the color of the menu text when not being rolled over
bordercolor="#000000";
borderstyle="none";
borderwidth=2;
separatorcolor="#7e807d";
separatorsize="0";
padding=3;
fontsize="10px";
fontstyle="normal";
fontfamily="Verdana, Tahoma, Arial";
pagecolor="#FFFFFF";
pagebgcolor="#615F58";
headercolor="#000000";
headerbgcolor="#ffffff";
subimage=scriptpath+"arrow.gif";
subimagepadding="0";
overfilter="Fade(duration=0.05);Shadow(color='#333333', Direction=135, Strength=5)";
outfilter="randomdissolve(duration=0.05)";
}

topStyle=new copyOf(menuStyle) 
topStyle.subimage="";

menuStyle.itemwidth=270;

with(milonic=new menuname("Main Menu")){
style=topStyle;
top=_menuTop;
left=0;
alwaysvisible=1;
orientation="horizontal";
overfilter="Fade(duration=0.0);"
aI("text=Home;url="+_server+";"+_globalRawCSS);
aI("text=Slide Library;url="+_server+"/slides;showmenu=Slides;"+_globalRawCSS);
aI("text=Virtual Meetings;url="+_server+"/meetings;showmenu=Meetings;"+_globalRawCSS);
aI("text=Commentaries on Research;url="+_server+"/commentaries;showmenu=Commentaries;"+_globalRawCSS);
aI("text=Clinical Cases;url="+_server+"/clinical-cases;showmenu=Cases;"+_globalRawCSS);
aI("text=CME Activities;url="+_server+"/cme;showmenu=CME;"+_globalRawCSS);
}

with(milonic=new menuname("Slides")){
style=menuStyle;
aI("text=Overview;url="+_server+"/slides;Status=none;separatorsize=1;separatorpadding=0;"+_globalRawCSS);
aI("text=Clinical Cases;url="+_server+"/slides/index.cfm#cases;showmenu=SlidesCases;"+_globalRawCSS);
aI("text=Evolving Concepts in Lipid Management;url="+_server+"/slides/index.cfm#combination;showmenu=SlidesConcepts;"+_globalRawCSS);
aI("text=ATP III: Updated Guidelines for Risk Assessment and Therapy;url="+_server+"/slides/index.cfm#atpiii;showmenu=SlidesATPIII;"+_globalRawCSS);
aI("text=HDL and Coronary Heart Disease;url="+_server+"/slides/index.cfm#hdl;showmenu=SlidesHDL;"+_globalRawCSS);
aI("text=Dyslipidemia, Diabetes and CHD;url="+_server+"/slides/index.cfm#chd;showmenu=SlidesDiabetes;"+_globalRawCSS);
aI("text=Dyslipidemia, Inflammation and Atherosclerosis;url="+_server+"/slides/index.cfm#athero;showmenu=SlidesInflammation;"+_globalRawCSS);
aI("text=Baylor College of Medicine Lipid Preceptorship;url="+_server+"/slides/index.cfm#bcmprecep;showmenu=SlidesPreceptorship;Status=none;separatorsize=1;separatorpadding=0;"+_globalRawCSS);
aI("text=Index of Slide Contents;url="+_server+"/slides/keywords.cfm;"+_globalRawCSS);
aI("text=Slide Library Help;url="+_server+"/slides/howto.cfm;"+_globalRawCSS);
}

with(milonic=new menuname("SlidesCases")){
style=menuStyle;
aI("text=The Patient with a Statin Intolerance;url="+_server+"/slides/slide01.cfm?tk=36;"+_globalRawCSS);
aI("text=Lipid Treatment and Goal Attainment: A Hispanic Male with CHD and Diabetes;url="+_server+"/slides/slide01.cfm?tk=34;"+_globalRawCSS);

}

with(milonic=new menuname("SlidesConcepts")){
style=menuStyle;
aI("text=C-Reactive Protein: A Marker of Risk;url="+_server+"/slides/slide01.cfm?tk=37;"+_globalRawCSS);
aI("text=C-Reactive Protein: A Target of Therapy;url="+_server+"/slides/slide01.cfm?tk=38;"+_globalRawCSS);
aI("text=Combination Lipid-Altering Drug Therapy with Statins: An Update;url="+_server+"/slides/slide01.cfm?tk=33;"+_globalRawCSS);
aI("text=Cholesterol Metabolism and the Concept of Dual Inhibition;url="+_server+"/slides/slide01.cfm?tk=31;"+_globalRawCSS);
aI("text=Sitosterolemia: A Rare Genetic Disorder Leads to Insight into an Important Physiological Process;url="+_server+"/slides/slide01.cfm?tk=29;"+_globalRawCSS);
}

with(milonic=new menuname("SlidesATPIII")){
style=menuStyle;
aI("text=Implications of Recent Clinical Trials for NCEP ATP III Guidelines ;url="+_server+"/slides/slide01.cfm?tk=32&pg=1;"+_globalRawCSS);
aI("text=Lifestyle Interventions: Dietary Therapy, Physical Activity, Weight Control;url="+_server+"/slides/slide01.cfm?tk=22;"+_globalRawCSS);
aI("text=Selecting Successful Lipid-Lowering Treatments;url="+_server+"/slides/slide01.cfm?tk=23;"+_globalRawCSS);
aI("text=ATP III: New Approaches in Identifying and Treating High-Risk Patients;url="+_server+"/slides/slide01.cfm?tk=24;"+_globalRawCSS);  
}

with(milonic=new menuname("SlidesHDL")){
style=menuStyle;
aI("text=HDL as a Therapeutic Target;url="+_server+"/slides/slide01.cfm?tk=25;"+_globalRawCSS);
aI("text=Epidemiology of CHD;url="+_server+"/slides/slide01.cfm?tk=9;"+_globalRawCSS);
aI("text=Physiology and Pathophysiology of HDL Metabolism;url="+_server+"/slides/slide01.cfm?tk=10;"+_globalRawCSS);
aI("text=Angiographic and Clinical Event Trials;url="+_server+"/slides/slide01.cfm?tk=11;"+_globalRawCSS);
aI("text=Effects of Lifestyle and Dietary Modification on HDL-C Levels;url="+_server+"/slides/slide01.cfm?tk=12;"+_globalRawCSS);
aI("text=Pharmacologic Therapy;url="+_server+"/slides/slide01.cfm?tk=13;"+_globalRawCSS);
}

with(milonic=new menuname("SlidesDiabetes")){
style=menuStyle;
aI("text=Update on the Metabolic Syndrome;url="+_server+"/slides/slide01.cfm?tk=30;"+_globalRawCSS);
aI("text=Epidemiology of Insulin Resistance, Diabetes Mellitus and CHD;url="+_server+"/slides/slide01.cfm?tk=14;"+_globalRawCSS);
aI("text=Diabetic Dyslipidemia and Atherosclerosis;url="+_server+"/slides/slide01.cfm?tk=17;"+_globalRawCSS);
aI("text=Clinical Trials and Guidelines for Lipid Management in the Diabetic Patient;url="+_server+"/slides/slide01.cfm?tk=15;"+_globalRawCSS);
aI("text=Clinical Evaluation and Nonlipid Treatment of CAD in the Diabetic Patient;url="+_server+"/slides/slide01.cfm?tk=16;"+_globalRawCSS);
}

with(milonic=new menuname("SlidesInflammation")){
style=menuStyle;
aI("text=Inflammatory Markers, Pharmacotherapy and Clinical Trials;url="+_server+"/slides/slide01.cfm?tk=21;"+_globalRawCSS);
aI("text=Inflammation and Pathogenesis of Atherothrombotic Disease;url="+_server+"/slides/slide01.cfm?tk=20;"+_globalRawCSS);
aI("text=Role of Lipoproteins in Inflammation;url="+_server+"/slides/slide01.cfm?tk=18;"+_globalRawCSS);
aI("text=Epidemiology of Inflammatory Markers and CHD;url="+_server+"/slides/slide01.cfm?tk=19;"+_globalRawCSS);
}

with(milonic=new menuname("SlidesPreceptorship")){
style=menuStyle;
aI("text=What is New with HDL and LDL Risk Assessment and Treatment;url="+_server+"/slides/slide01.cfm?tk=7;"+_globalRawCSS);
aI("text=Role of Fibrates in Lipid Treatment;url="+_server+"/slides/slide01.cfm?tk=5;"+_globalRawCSS);
aI("text=New Options for Managing Dyslipidemia and Reducing CHD;url="+_server+"/slides/slide01.cfm?tk=3;"+_globalRawCSS);
aI("text=Emerging CHD Risk Factors and New Approaches to Risk Assessment;url="+_server+"/slides/slide01.cfm?tk=8;"+_globalRawCSS);
aI("text=Achieving Partnership to Effectively Implement a Lipid Management System;url="+_server+"/slides/slide01.cfm?tk=6;"+_globalRawCSS);
aI("text=Computer Databases for Tracking Your Patients;url="+_server+"/slides/slide01.cfm?tk=1;"+_globalRawCSS);
aI("text=Quality Assurance within Your Practice;url="+_server+"/slides/slide01.cfm?tk=2;"+_globalRawCSS);
}

with(milonic=new menuname("Meetings")){
style=menuStyle;
aI("text=Overview;url="+_server+"/meetings;Status=none;separatorsize=1;separatorpadding=0;"+_globalRawCSS);
aI("text=Pathways from Insulin Resistance to Cardiovascular Disease: New Insights into Management and Prevention;url="+_server+"/meetings/pathways;"+_globalRawCSS);
aI("text=New Strategies for New Targets;url="+_server+"/meetings/targets;"+_globalRawCSS);
aI("text=Achieving Current and Future LDL-C Targets in Daily Practice;url="+_server+"/meetings/daily_practice;"+_globalRawCSS);
}

with(milonic=new menuname("commentaries")){
style=menuStyle;
aI("text=Overview;url="+_server+"/commentaries;Status=none;separatorsize=1;separatorpadding=0;"+_globalRawCSS);
aI("text=Commentaries on Recent Publications;url="+_server+"/commentaries;showmenu=CommentariesRecent;"+_globalRawCSS);
aI("text=Commentaries Prior to March 2002;url="+_server+"/commentaries;showmenu=CommentariesPrior;"+_globalRawCSS);
aI("text=Commentaries on In-Hospital Initiation of Lipid Regulating Therapy;url="+_server+"/commentaries;showmenu=CommentariesInhospital;"+_globalRawCSS);
}

with(milonic=new menuname("CommentariesRecent")){
style=menuStyle;
aI("text=Collaborative Atorvastatin Diabetes Study (CARDS);url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs054;"+_globalRawCSS);
aI("text=Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT);url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs049;"+_globalRawCSS);
aI("text=Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL);url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs048;"+_globalRawCSS);
aI("text=The Apo A-I Milano Trial;url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs047;"+_globalRawCSS);
aI("text=Coronary Heart Disease Risk in Women’s Health Initiative: Updated Analysis ;url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs046;"+_globalRawCSS);
aI("text=Glycemic Control Slows Rates of Carotid Artery Disease Progression;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs045;"+_globalRawCSS);
aI("text=The Heart Protection Study (HPS) of Cholesterol Lowering with Simvastatin in Diabetics;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs044;"+_globalRawCSS);
aI("text=Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA);url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs043;"+_globalRawCSS);
aI("text=C-Reactive Protein, Metabolic Syndrome, and Cardiovascular Events in Women;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs041;"+_globalRawCSS);
aI("text=AHA/CDC Scientific Statement on C-Reactive Protein and Other Inflammatory Markers;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs042;"+_globalRawCSS);
aI("text=The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT);url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs039;"+_globalRawCSS);
aI("text=The Bypass Angioplasty Revascularization Investigation (BARI) and Non–High-Density Lipoprotein Cholesterol;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs040;"+_globalRawCSS);
aI("text=C-Reactive Protein Levels and Risk for First Cardiovascular Events in Women;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs037;"+_globalRawCSS);
aI("text=Prospective Study of Pravastatin in the Elderly at Risk (PROSPER);url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs038;"+_globalRawCSS);
aI("text=Fluvastatin for Prevention of Cardiac Events Following Successful First PCI;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs036;"+_globalRawCSS);
aI("text=Early Statin Initiation in Acute Coronary Syndromes;url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs035;"+_globalRawCSS);
aI("text=Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs034;"+_globalRawCSS);
aI("text=Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy;url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs033;"+_globalRawCSS);
aI("text=Coronary Heart Disease in Patients with Low LDL-C;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs031;"+_globalRawCSS);
aI("text=Withdrawal of Statins Increases Event Rates in Patients with Acute Coronary Syndromes;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs030;"+_globalRawCSS);
}

with(milonic=new menuname("CommentariesPrior")){
style=menuStyle;
aI("text=Inflammatory Markers and Endothelial Function in Obesity and After Weight Loss;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs029;"+_globalRawCSS);
aI("text=The Diabetes Prevention Program;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs018;"+_globalRawCSS);
aI("text=HDL-Atherosclerosis Treatment Study (HATS);url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs024;"+_globalRawCSS);
aI("text=Influence of Low HDL-C and Elevated Triglyceride on CHD Events and Response to Simvastatin in 4S;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs028;"+_globalRawCSS);
aI("text=Low-Density Lipoprotein Size, Pravastatin Treatment, and Coronary Events;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs022;"+_globalRawCSS);
aI("text=Effect of Fenofibrate on the Progression of Coronary-Artery Disease in Type 2 Diabetes: the Diabetes Atherosclerosis Intervention Study, a Randomised Study;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs023;"+_globalRawCSS);
aI("text=Coronary Heart Disease Prediction from Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein, Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs020;"+_globalRawCSS);
aI("text=Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. The MIRACL Study: A randomized controlled trial;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs021;"+_globalRawCSS);
aI("text=Effects of Endurance Exercise Training on Plasma HDL Cholesterol Levels Depend on Levels of Triglycerides;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs019;"+_globalRawCSS);
aI("text=Non-High-Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs017;"+_globalRawCSS);
aI("text=Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs009;"+_globalRawCSS);
}

with(milonic=new menuname("CommentariesInhospital")){
style=menuStyle;
aI("text=Use of lipid-lowering medications at discharge in patients with acute myocardial infarction;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs013;"+_globalRawCSS);
aI("text=Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs014;"+_globalRawCSS);
aI("text=Early statin treatment following acute myocardial infarction and 1-year survival;url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs015;"+_globalRawCSS);
aI("text=Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study);url="+_server+"/commentaries/al_abstract.cfm?abs_id=Abs016;"+_globalRawCSS);
}

with(milonic=new menuname("cases")){
style=menuStyle;
aI("text=Overview;url="+_server+"/clinical-cases;Status=none;separatorsize=1;separatorpadding=0;"+_globalRawCSS);
aI("text=The Patient with a Statin Intolerance;url="+_server+"/clinical-cases/statin-intolerance;"+_globalRawCSS);
aI("text=Lipid Treatment and Goal Attainment: A Hispanic Male with CHD and Diabetes;url="+_server+"/clinical-cases/diabetes;"+_globalRawCSS);

}


with(milonic=new menuname("cme")){
style=menuStyle;
aI("text=Overview;url="+_server+"/cme;Status=none;separatorsize=1;separatorpadding=0;"+_globalRawCSS);
aI("text=Clinical Cases;url="+_server+"/cme;showmenu=CMETreatment;"+_globalRawCSS);
aI("text=Recent Research;url="+_server+"/cme;showmenu=CMEResearch;"+_globalRawCSS);
aI("text=New Guidelines and New Evidence;url="+_server+"/cme;showmenu=CMEGuidelines;"+_globalRawCSS);
}

with(milonic=new menuname("CMETreatment")){
style=menuStyle;

aI("text=The Patient with a Statin Intolerance;url="+_server+"/clinical-cases/statin-intolerance;"+_globalRawCSS);
aI("text=Lipid Treatment and Goal Attainment: A Hispanic Male with CHD and Diabetes ;url="+_server+"/clinical-cases/diabetes;"+_globalRawCSS);

}

with(milonic=new menuname("CMEResearch")){
style=menuStyle;
aI("text=Collaborative Atorvastatin Diabetes Study (CARDS);url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs054&cmepage=cme_info&cme_activityid=93;"+_globalRawCSS);
aI("text=Pathways from Insulin Resistance to Cardiovascular Disease: New Insights into Management and Prevention;url="+_server+"/meetings/pathways;"+_globalRawCSS);
aI("text=New Strategies for New Targets;url="+_server+"/meetings/targets;"+_globalRawCSS);
aI("text=Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT);url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs049&cmepage=cme_info&cme_activityid=70;"+_globalRawCSS);
aI("text=Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL);url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs048&cmepage=cme_info&cme_activityid=67;"+_globalRawCSS);
aI("text=The Apo A-I Milano Trial;url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs047&cmepage=cme_info&cme_activityid=53;"+_globalRawCSS);
aI("text=Coronary Heart Disease Risk in Women’s Health Initiative: Updated Analysis;url="+_server+"/commentaries/al_abstract.cfm?abs_id=abs046&cmepage=cme_info&cme_activityid=43;"+_globalRawCSS);
aI("text=Glycemic Control Slows Rates of Carotid Artery Disease Progression;url="+_server+"/commentaries/abs_cme.cfm?cme_id=66&show=info;"+_globalRawCSS);
aI("text=The Heart Protection Study (HPS) of Cholesterol Lowering with Simvastatin in Diabetics;url="+_server+"/commentaries/abs_cme.cfm?cme_id=65&show=info;"+_globalRawCSS);
aI("text=The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT);url="+_server+"/commentaries/abs_cme.cfm?cme_id=5&show=info;"+_globalRawCSS);
aI("text=The Bypass Angioplasty Revascularization Investigation (BARI) and Non–High-Density Lipoprotein Cholesterol;url="+_server+"/commentaries/abs_cme.cfm?cme_id=6&show=info;"+_globalRawCSS);
aI("text=New Trial Results on the Risk/Benefit of Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease;url="+_server+"/commentaries/abs_cme.cfm?cme_id=1&show=info;"+_globalRawCSS);
}

with(milonic=new menuname("CMEGuidelines")){
style=menuStyle;
aI("text=C-Reactive Protein: A Marker or Target of Therapy;url="+_server+"/slides/talk_cme_activity.cfm?tk=37&cmepage=cme_info;"+_globalRawCSS);
aI("text=Combination Lipid-Altering Drug Therapy with Statins: An Update;url="+_server+"/slides/talk_cme_activity.cfm?tk=33&cme_activityid=94&cmepage=cme_info;"+_globalRawCSS);
aI("text=Implications of Recent Clinical Trials for NCEP ATP III Guidelines;url="+_server+"/slides/talk_cme_activity.cfm?tk=32&cme_activityid=75&cmepage=cme_info;"+_globalRawCSS);
aI("text=Cholesterol Metabolism and the Concept of Dual Inhibition;url="+_server+"/slides/talk_cme_activity.cfm?tk=31&cme_activityid=71&cmepage=cme_info;"+_globalRawCSS);
aI("text=Update on the Metabolic Syndrome;url="+_server+"/slides/talk_cme_activity.cfm?tk=30&cme_activityid=49&cmepage=cme_info;"+_globalRawCSS);
aI("text=Sitosterolemia: A Rare Genetic Disorder Leads to Insight into an Important Physiological Process;url="+_server+"/slides/talk_cme_activity.cfm?tk=29&cme_activityid=48&cmepage=cme_info;"+_globalRawCSS);
aI("text=Achieving Current and Future LDL-C Targets in Daily Practice;url="+_server+"/meetings/daily_practice;"+_globalRawCSS);
}
drawMenus();